4-nitrophenyl acetate has been researched along with Kidney Failure, Chronic in 1 studies
*Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Furukubo, T; Hojo, A; Izumi, S; Katsube, Y; Koide, H; Minegaki, T; Nishiguchi, K; Ochiai, M; Shima, D; Tsujimoto, M; Yamakawa, T | 1 |
1 other study(ies) available for 4-nitrophenyl acetate and Kidney Failure, Chronic
| Article | Year |
|---|---|
Acceleration of carboxylesterase-mediated activation of irinotecan to SN-38 by serum from patients with end-stage kidney disease.
Topics: Carboxylesterase; Case-Control Studies; Fatty Acids; Humans; Irinotecan; Kidney Failure, Chronic; Microsomes, Liver; Nitrophenols; Topoisomerase I Inhibitors; Uremia | 2018 |